# A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

> **NCT05704725** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 49 (actual)

## Conditions studied

- Chorioretinal Vascular Disease

## Interventions

- **DRUG:** ABP 938
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT05704725
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-23
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-03-24
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704725, "A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05704725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*